awarded today:
$598,788 — The grant supports a joint effort between researchers at University of Massachusetts, Lowell, and Natick, MA-based medical devices giant Boston Scientific (NYSE:[[ticker:BSX]]) aimed at developing novel coatings for pacemaker and defibrillator leads.
$750,000 — Judy Lieberman, a professor of pediatrics at Harvard Medical School, is working with the Immune Disease Institute in Boston and Epic Therapeutics of Norwood, MA, on a study of the antiviral effects of microparticles combined with small interfering RNA. The research may lead to development of a topical treatment to prevent sexual transmission of herpes simplex virus (HSV-2).
$750,000 — David Weitz, a physics professor at Harvard University, is collaborating with Raindance Technologies, a Lexington, MA-based developer of genetic research tools, to develop florescence-activated cell sorter.
$189,300 — Andrew Luster, a physician at Massachusetts General Hospital in Boston, will work with Cambridge, MA-based biotech firm Idera Pharmaceuticals (NADAQ:[[ticker:IDRA]]) to develop new treatments for autoimmune diseases like Lupus.
$750,000 — Richard Lee, a researcher at Brigham and Women’s Hospital, and Parth Patwari of Harvard Medical School plan to work with Biomeasure, based in Milford, MA, on a study of a heparin-binding protein that could boost cartilage regeneration for patients with osteoarthritis or those who suffer traumatic injuries.
$750,000 — UMass Medical School researchers Michael Czech and Gary Ostroff plan to collaborate with RXi Pharmaceuticals (NASDAQ:[[ticker:RXII]]), based in Worcester, MA, on the development of orally delivered RNA-interference drugs. Czech is listed on the company’s Web site as a founder of RXi and a member of the scientific advisory board.
